Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Viracta Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mark Rothera

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi	40.5%
CEO görev süresi	2.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

Viracta Therapeutics names Mark Rothera as new CEO

Sep 19

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

Sep 07

Viracta Therapeutics GAAP EPS of -$0.28

Aug 09

Viracta Therapeutics files for $200M mixed shelf offering

May 28

CEO Tazminat Analizi

Mark Rothera'un ücretlendirmesi Viracta Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$1m	US$590k	-US$51m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$6m	US$167k	-US$49m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 1.46M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Mark 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mark Rothera (61 yo)

2.1yrs

Görev süresi

US$1,456,596

Tazminat

Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Rothera	CEO, President & Director	2.1yrs	US$1.46m	Veri yok
Darrel Cohen	Chief Medical Officer	1.2yrs	US$1.05m	0% $ 0
Susan Perrine	Scientific Founder and Consultant	13.8yrs	Veri yok	Veri yok
Ronald Berenson	Co-Founder and Consultant	13.8yrs	Veri yok	Veri yok
George Hillman	Co-Founder	no data	Veri yok	Veri yok
Thalia Papayannopoulou	Co-Founder	no data	Veri yok	Veri yok
Robert Williams	Co-Founder	no data	Veri yok	Veri yok
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Faerm	Chief Financial Officer	less than a year	Veri yok	Veri yok
Ayman El-Guindy	Chief Scientific Officer	3.3yrs	Veri yok	Veri yok
Cheryl Madsen	Senior Vice President of Regulatory Affairs	3.6yrs	Veri yok	Veri yok
Patric Nelson	Senior Vice President of Business Development & Corporate Strategy	3.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: VIRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Rothera	CEO, President & Director	2.1yrs	US$1.46m	Veri yok
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Ivor Royston	Director	3.7yrs	US$90.76k	2.11% $ 191.5k
Thomas Darcy	Independent Director	3.7yrs	US$113.26k	0% $ 0
Ronald Levy	Member of Scientific Advisory Board	6.1yrs	Veri yok	Veri yok
Carl June	Member of Scientific Advisory Board	6.1yrs	Veri yok	Veri yok
Barry Simon	Independent Director	3.6yrs	US$110.76k	0% $ 0
Roger Pomerantz	Independent Chairman of the Board	3.7yrs	US$210.27k	0.30% $ 27.0k
Lawrence Young	Member of Scientific Advisory Board	6.1yrs	Veri yok	Veri yok
Robert Baiocchi	Member of Scientific Advisory Board	6.1yrs	Veri yok	Veri yok
Pierluigi Porcu	Member of Scientific Advisory Board	6.1yrs	Veri yok	Veri yok
Stephen Rubino	Independent Director	3.6yrs	US$108.26k	0% $ 0

3.7yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VIRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Viracta Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

High number of new directors

High number of new directors

Recent updates

New major risk - Market cap size

New major risk - Financial position

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

New major risk - Revenue and earnings growth

Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1)

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

New major risk - Revenue and earnings growth

Price target decreased by 20% to US$7.00

Viracta Therapeutics, Inc. Provides Clinical Update

Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Price target decreased by 36% to US$9.40

Price target decreased by 9.1% to US$14.00

Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients

Price target decreased to US$15.00

High number of new directors

High number of new directors

High number of new directors

Viracta Therapeutics, Inc. Announces CEO Changes

Viracta Therapeutics names Mark Rothera as new CEO

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

CEO, President & Director exercised options and sold US$54k worth of stock

Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics GAAP EPS of -$0.28

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index

Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Price target decreased to US$21.40

Less than half of directors are independent

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

Price target increased to US$31.50

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

CEO, President & Director exercised options and sold US$133k worth of stock

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Viracta Therapeutics files for $200M mixed shelf offering

Viracta Therapeutics, Inc. Announces Executive Changes

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş